AUTHOR=Kaufmann Stefan H. E. , Dockrell Hazel M. , Drager Nick , Ho Mei Mei , McShane Helen , Neyrolles Olivier , Ottenhoff Tom H. M. , Patel Brij , Roordink Danielle , Spertini François , Stenger Steffen , Thole Jelle , Verreck Frank A. W. , Williams Ann , TBVAC2020 Consortium , Britton Warwick , Triccas Jamie , Counoupas Claudio , Grooten Johan , Demoitie Marie-Ange , Romano Marta , Mascart Francoise , Andersen Peter , Aagaard Claus , Christensen Dennis , Ruhwald Morten , Lindenstrom Thomas , Neyrolles Olivier , Charneau Pierre , Guilhot Christophe , Peixoto Antonio , Gilleron Martine , Locht Camille , Brosch Roland , Inchauspe Genevieve , Long Stephane Leung Theung , Kaufmann Stefan , Weiner January , Maertzdorf Jeroen , Neuwenhuizen Natalie , Bastian Max , Stenger Steffen , Caccamo Nadia , Goletti Delia , Nisini Roberto , Shin Sung Jae , Lee Hyejon , Sigal Alex , Scriba Thomas , Walzl Gerhard , Loxton Andre , Wilkinson Robert , Cardona Pere-Joan , Vilaplana Cris , Martin Carlos , Marinova Dessi , Aguilo Nacho , Spertini François , Aebersold Ruedi , Caron Etienne , Pinschewer Daniel , De Libero Gennaro , Siegrist Claire Anne , Collin Nicolas , Barnier-Quer Christophe , Sander Peter , Verreck Frank , Ottenhoff Tom , Joosten Simone , van Meijgaarden Krista , Coppola Mariateresa , Geluk Annemieke , Drager Nick , Roordink Danielle , Thole Jelle , Perrie Yvonne , Baird Marc , Levin Michael , Dockrell Hazel , Smith Steven , Fletcher Helen , Bancroft Gregory , Rawkins Ann , Clark Simon , Ho Mei Mei , McShane Helen , Satti Iman , Stylianou Elena , Vordermeier Martin , Hogarth Philip TITLE=TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development JOURNAL=Frontiers in Immunology VOLUME=8 YEAR=2017 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01203 DOI=10.3389/fimmu.2017.01203 ISSN=1664-3224 ABSTRACT=

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.